14-day Premium Trial Subscription Try For FreeTry Free
RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of MGNX
Powered by GPT-4o
Stock Analysis
Risk Assessment
Trading Strategy

MacroGenics stock price up more than 6.07% on Friday
(Updated on Jun 21, 2024)

Sell candidate since May 08, 2024 Loss -70.19% PDF

The MacroGenics stock price gained 6.07% on the last trading day (Friday, 21st Jun 2024), rising from $4.12 to $4.37. During the last trading day the stock fluctuated 8.42% from a day low at $4.04 to a day high of $4.38. The price has fallen in 5 of the last 10 days and is down by -6.42% for this period. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 5 million more shares were traded than the day before. In total, 6 million shares were bought and sold for approximately $26.68 million.

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Due to the high volatility and the trend direction we are not able to give forecast range for this stock. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

MGNX Signals & Forecast

There are mixed signals in the stock today. The MacroGenics stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $4.43 and $6.33. A break-up above any of these levels will issue buy signals. A buy signal was issued from a pivot bottom point on Friday, May 10, 2024, and so far it has risen 32.02%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Volume is rising along with the price. This is considered to be a good technical signal.

Support, Risk & Stop-loss for MacroGenics stock

MacroGenics finds support from accumulated volume at $4.37 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $0.340 between high and low, or 8.42%. For the last week, the stock has had daily average volatility of 6.48%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (MGNX) For The Upcoming Trading Day Of Monday 24th

For the upcoming trading day on Monday, 24th we expect MacroGenics to open at $4.26, and during the day (based on 14 day Average True Range), to move between $3.81 and $4.93, which gives a possible trading interval of +/-$0.562 (+/-12.85%) up or down from last closing price. If MacroGenics takes out the full calculated possible swing range there will be an estimated 25.71% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $4.37 (0.11%) than the resistance at $4.38 (0.23%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Is MacroGenics stock A Buy?

MacroGenics holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.

Current score: -2.138 Sell Candidate Unchanged

Predicted Opening Price for MacroGenics of Monday, June 24, 2024

Fair opening price June 24, 2024 Current price
$4.26 ( 2.44%) $4.37

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for MGNX

Fibonacci Support & Resistance Levels

Level Price
R3 4.60 5.34%
R2 4.47 2.37%
R1 4.39 0.531%
Price 4.37
S1 4.13 -5.41%
S2 4.05 -7.25%
S3 3.92 -10.22%

Accumulated Volume Support & Resistance Levels

Level Price
R3 4.48 2.52%
R2 4.45 1.83%
R1 4.38 0.229%
Price 4.37
S1 4.37 -0.114%
S2 4.26 -2.52%
S3 3.31 -24.26%


What is the symbol for MacroGenics Stock and on which exchange is it traded?
The symbol for MacroGenics is MGNX and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell MacroGenics Stock?
MacroGenics holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.

How to buy MacroGenics Stock?
MacroGenics Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy MacroGenics Stock.

What's the current price of MacroGenics Stock?
As of the end of day on the Jun 21, 2024, the price of an MacroGenics (MGNX) share was $4.37.

What is the 52-week high and low for MacroGenics Stock?
The 52-week high for MacroGenics Stock is $21.88 and the 52-week low is $3.15.

What is the market capitalization of MacroGenics Stock?
As of the Jun 21, 2024, the market capitalization of MacroGenics is 258.05M.

When is the next earnings date for MacroGenics?
The upcoming earnings date for MacroGenics is Aug 14, 2024.
Click to get the best stock tips daily for free!

About MacroGenics

MacroGenics MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The... MGNX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE